DTPw-HBV/Hib-MenAC conjugate vaccine
Sponsors
GlaxoSmithKline
Conditions
DiphtheriaDiphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell PertussisHaemophilus Influenzae Type bHepatitis BHib DiseasesNeisseria Meningitidis Serogroups A & C DiseasesPertussisTetanus
Phase 2
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
CompletedNCT00291967
Start: 2002-11-30Target: 525Updated: 2006-12-08
A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
CompletedNCT00317174
Start: 2003-07-31End: 2004-04-30Target: 450Updated: 2016-09-09
Phase 3
Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants
CompletedNCT00290303
Start: 2004-05-31End: 2005-03-31Updated: 2016-09-16
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.
CompletedNCT00317161
Start: 2004-08-31End: 2005-04-30Updated: 2016-09-20
Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth
CompletedNCT00317122
Start: 2004-10-31End: 2005-07-31Updated: 2016-09-21